[1] National Center for ADR Monitoring, China. Annual Reports on Adverse Drug Reaction Monitoring (2023)[EB/OL]. (2024-03-26)[2024-06-27]. https://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_sjbg/202403/t20240326_50614.html. [2] NMPA. Good Pharmacovigilance Practice[EB/OL]. (2021-05-13)[2024-06-25]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210513151827179.html. [3] ZHU L, ZHU Y, LIU LH, et al.Common Problems with Post-marketing Adverse Drug Reaction Reports from Literature[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(12): 1155-1158. [4] NMPA. List of Typical Application Scenarios of Artificial Intelligence in Drug Regulation[EB/OL]. (2024-06-13)[2024-06-18]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210513151827179.html. [5] AI KUWAITI A, NAZER K, AI-REEDY A, et al.A Review of the Role of Artificial Intelligence in Healthcare[J]. Journal of Personalized Medicine, 2023, 13(6): 951. [6] The Ministry of Industry and Information Technology and Six Other Departments. Implementation Plan for Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)[EB/OL]. (2025-04-24)[2025-08-18]. https://www.nmpa.gov.cn/xxgk/fgwj/qita/20250425170354149.html. [7] CIOMS. Artificial Intelligence in Pharmacovigilance Proposal[EB/OL]. (2022-02-02)[2024-07-03]. https://cioms.ch/wp-content/uploads/2022/05/CIOMS-Concept-Note-on-AI-in-PV_final-02.02.2022.pdf. [8] NÉVÉOL A, DALIANIS H, VELUPILLAI S, et al. Clinical Natural Language Processing in Languages Other Than English: Opportunities and Challenges[J]. Journal of Biomedical Semantics, 2018, 9(1): 1-13. [9] GONG YS, CAI KP, WANG ZQ, et al.Semi-Automatic Text Category Labelling Method Based on Machine Learning[J].Chinese Journal of Engineering Mathematics(工程数学学报), 2021, 38(6): 750-762. [10] GU JM, TANG CQ, JIANG Y, et al.A Case Report of Acute Kidney Injury Caused by Semaglutide in Combination with Multiple Medications[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2025, 34(7): 835-840. [11] LI WH, HAKEN B.Computer Vision-ECCV 2020 Workshops[C]. Glasgow, United Kingdom: Springer, 2021. [12] GU H, JIANG HD.Retinal Hemorrhage Caused by Gefitinib[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2021, 23(1): 52-53. [13] TOMOVIC S, PAVLOVIC K, BAJCETA M.Aligning Document Layouts Extracted with Different OCR Engines with Clustering Approach[J]. Egyptian Informatics Journal, 2021, 22: 239-338. [14] BRUCE P. The Future of Pharmacovigilance is Proactive[EB/OL]. (2024-03-04)[2024-07-16]. https://www.contractpharma.com/the-future-of-pharmacovigilance-is-proactive-210022/. [15] WANG T, ZHENG MJ, LIU HL, et al.Current Applications of Artificial Intelligence in Pharmacovigilance in the USA and Implications[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(10): 1129-1133. [16] LIANG HS, CHEN JQ.Research on Ethical Problems of Application of Generative Artificial Intelligence in Medical Field[J]. Journal of Jinzhou Medical University (Social Science Edition)(锦州医科大学学报社会科学版), 2024, 22(3): 19-22. [17] The State Council of The People’s Republic of CHINA. Notice by Six Departments Including the Ministry of Science and Technology of Issuing the Guiding Opinions on Accelerating Scenario Innovation and Promoting High-Quality Economic Development with High-Level Application of Artificial Intelligence[EB/OL]. (2022-07-29)[2024-07-10]. https://www.gov.cn/zhengce/zhengceku/2022-08/12/content_5705154.htm. [18] CHENG L. The Status, Challenges and Prospects of Generative Artificial Intelligence Governance[J]. People's Tribune(人民论坛), 2024, 2: 76-81. [19] CIOMS. Artificial intelligence in Pharmacovigilance Proposal Working Group Report[EB/OL]. (2025-05-01)[2025-08-14]. https://CIOMS-WG-XIV_Draft-report-for-Public-Consultation_1May-2025.pdf. [20] ZHANG X.Algorithmic Governance Challenges and Governance-Based Supervision of Generative Artificial Intelligence[J]. Modern Law Science, 2023, 45(3): 108-123. [21] CHEN HG, AN SF.Research on the Risks and Governance of Generative Artificial Intelligence Training Data[J]. Journal of Hainan Open University(海南开放大学学报), 2024, 94(1): 110-118. [22] T/SBIAORG 0002-2025 0002-2025. Specifications of AI-Assisted Data Extraction for Individual Case Safety Reports in Pharmacovigilance Based on Large Language Models(基于大语言模型的药物警戒个例安全性报告人工智能辅助信息提取规范)[S]. Beijing: Standards Press of China, 2025. [23] WANG T, ZHANG L, WANG Q, et al.Analysis of the Current Application Status and Enlightenment of Artificial Intelligence in Post-marketing Pharmacovigilance in China[J]. Herald of Medicine(医药导报), 2025, 44(4): 560-564. [24] Laborp Drug Development. The Future of Pharmacovigilance[EB/OL]. (2019-09-12)[2024-07-16]. https://www.labcorp.com/future-pharmacovigilance. |